Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.65 USD | +3.80% | -0.39% | -36.30% |
May. 21 | Accolade, Inc. Welcomes Noom to Trusted Partner Ecosystem | CI |
Apr. 30 | Wells Fargo Cuts Price Target on Accolade to $10 From $12, Maintains Equalweight Rating | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 66% by 2027.
- The company is in a robust financial situation considering its net cash and margin position.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-36.30% | 577M | C- | ||
+17.73% | 83.47B | C+ | ||
-32.08% | 69.72B | B- | ||
-3.24% | 26.37B | C+ | ||
+4.13% | 17.86B | A- | ||
-13.68% | 16.83B | B | ||
+0.75% | 15.7B | A- | ||
+74.92% | 13.45B | C- | ||
+73.16% | 12.81B | C+ | ||
-2.02% | 12.44B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ACCD Stock
- Ratings Accolade, Inc.